Clinical Trial

Ablation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation

Study acronym: TerFib
Recruiting
View on ClinicalTrials.gov →
Summary
The mechanisms that maintain persistent atrial fibrillation (AF) in humans remain unknown. In the research project PI18/01268 funded in the previous call for Strategic Action in Health, the group has demonstrated that the hierarchical organization of (i) rotational domains, (ii) frequency domains and (iii) physiological responses to pharmacological provocation with adenosine, allow the identification of domains of high-frequency reentrant activity (hereinafter "DFASI domains") maintainers of AF. As a result, the investigators have developed non-invasive technological models and quantitative indices for the efficient localization of these domains, whose therapeutic approach through ablation has allowed to improve the clinical results of the patients studied, safely without increase in complications (Calvo D et al. Sci Rep. 2025 Dec 16;15(1):43892). Likewise, and in response to the objectives of the PI18/01268 project, the investigators have identified hierarchical organization patterns in human ventricular fibrillation (VF) that indicate the existence of universal fibrillatory mechanisms, opening the door to new therapeutic opportunities (Europace 2022;24\[11\]:1788-1799).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-28; most recent amendment 2026-02-18.
Trial Details
NCT Number NCT07390175
Lead Sponsor Hospital San Carlos, Madrid
Collaborators: Instituto de Salud Carlos III
Conditions Atrial Fibrillation (AF), Ablation Treatment, TerFib_Hyerarchy
Enrollment 78 participants
Start Date 2025-01-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-20